A DECADE OF EXPERIENCE

SUBTITLE: WITH BRAATHENS OUT OF SWEDEN AND NEW DASH 8-Q400S ARRIVING, SAS COMMUTER HAS BECOME A GROWNUP IN SAS GROUP.

[1]  D. DeMeo,et al.  Clinical status of lung transplantation. , 2001, Transplantation.

[2]  R. Novick,et al.  Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  David O. Taylor.  Immunosuppressive therapies after heart transplantation: best, better, and beyond , 2000, Current opinion in cardiology.

[4]  A. J. Chandrasekhar,et al.  Analysis of risk factors for the development of bronchiolitis obliterans syndrome. , 1999, American journal of respiratory and critical care medicine.

[5]  A. Haverich,et al.  ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference? , 1998, Transplantation proceedings.

[6]  G. Berry,et al.  Risk factors for the development of obliterative bronchiolitis after lung transplantation. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  G. Berry,et al.  Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[8]  D. Kapelanski,et al.  Lung transplantation without the use of antilymphocyte antibody preparations. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[9]  E. Trulock,et al.  Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. , 2000, Clinical transplants.